



## Abstract presented at the 11th Trends in Medical Mycology publicly available

Stockholm, Sweden – October 23, 2023 – Biosergen AB (“Biosergen” or the “Company”), a clinical-stage biotech company specializing in the development of innovative anti-fungal therapies, today announced that the company’s abstract about the drug candidate BSG005, which was presented at the 11th Trends in Medical Mycology, on October 21, 2023, is now publicly available

The abstract presentation, given by Biosergen’s COO Tine Olesen, laid out that single and multiple dose intravenous infusions of BSG005 were safe in healthy subjects. Adverse events were mild to moderate in severity, the majority of adverse events being infusion-related in the single ascending dose part of the trial and phlebitis in the multi ascending dose part of the trial, and no severe adverse events were seen in the study. Also, basic pharmacovigilance parameters were established.

Biosergen’s COO, Tine Olesen, who presented the data to the conference audience, stated, “The engaging discussions and insights shared during the conference further highlight the need for novel anti-fungal treatments. It was a pleasure to be able to contribute to this scientific conversation with our encouraging data on BSG005.”

The title of the abstract is “First in human data on BSG005, a genetically engineered polyene macrolide evaluated in a double-blinded placebo-controlled Phase 1 trial” and is accessible on the [conference website](#) and attached to this release.

Currently, Biosergen and its partner Alkem Laboratories Ltd. are preparing a Phase 2 clinical trial in India. The trial will enrol patients suffering from severe fungal infections such as mucormycosis, aspergillosis, and candidiasis. Based on the safety and efficacy profile demonstrated in the preclinical studies and the phase I trials, as also published in the above-mentioned abstract, BSG005 may provide a suitable treatment option for these patients.

### **For more information**

#### **For further information about Biosergen, please contact:**

Dr. Peder M. Andersen, CEO

Telephone: +45 2080 2470

E-mail: [peder.andersen@biosergen.net](mailto:peder.andersen@biosergen.net)

Niels Lauren, CFO

Telephone: +45 4014 5059

E-mail: [niels.laursen@biosergen.net](mailto:niels.laursen@biosergen.net)

#### **Certified Adviser**

Erik Penser Bank

### **ABOUT BIOSERGEN**

Biosergen is a leading clinical-stage biotechnology company at the forefront of antifungal drug

development. Our mission is to develop BSG005, our lead drug candidate, into the new first-line treatment choice for invasive fungal diseases, while generating significant returns for our shareholders. Our Phase I trial showcased the exceptional safety and tolerability of BSG005, especially when compared to existing alternatives. Building on those results we are now advancing to test the drug in patients expected to clinically validate BSG005's potential as a new and strong antifungal treatment. Biosergen's development of BSG005 is based on two decades of scientific work at the Norwegian University of Science and Technology. For more information, visit [www.biosergen.net](http://www.biosergen.net).